BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rehman O, Jaferi U, Padda I, Khehra N, Atwal H, Mossabeh D, Bhangu R. Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma. Clin Exp Hepatol 2021;7:249-57. [PMID: 34712825 DOI: 10.5114/ceh.2021.109312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Singh AK, Singh SV, Kumar R, Kumar S, Senapati S, Pandey AK. Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise . World J Hepatol 2023; 15(1): 1-18 [DOI: 10.4254/wjh.v15.i1.1] [Reference Citation Analysis]
2 Tang Y, Yuan F, Cao M, Li Y, Ren Y, Yang G, Zhong Z, He Z, Nan L, Deng M, Yao Z. CircRNA-mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance via PSIP1/c-Myc Axis Nuclear Translocation and Partially through Increasing EGFR Expression.. [DOI: 10.21203/rs.3.rs-2437109/v1] [Reference Citation Analysis]
3 Wang S, Wang Y, Yu J, Wu H, Zhou Y. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14. [PMID: 36428618 DOI: 10.3390/cancers14225525] [Reference Citation Analysis]
4 Limpachayaporn P, Nuchpun S, Sirirak J, Charoensuksai P, Wongprayoon P, Chuaypen N, Tangkijvanich P, Suksamrarn A. meta-Ureidophenoxy-1,2,3-triazole hybrid as a novel scaffold for promising HepG2 hepatocellular carcinoma inhibitors: Synthesis, biological evaluation and molecular docking studies. Bioorganic & Medicinal Chemistry 2022;74:117048. [DOI: 10.1016/j.bmc.2022.117048] [Reference Citation Analysis]
5 Jiang W, Zhao T, Zhen X, Jin C, Li H, Ha J. Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS. Front Pharmacol 2022;13:920436. [DOI: 10.3389/fphar.2022.920436] [Reference Citation Analysis]
6 Matrone A, Gambale C, Prete A, Elisei R. Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine. Front Endocrinol 2022;13:864253. [DOI: 10.3389/fendo.2022.864253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Hou W, Bridgeman B, Malnassy G, Ding X, Cotler SJ, Dhanarajan A, Qiu W. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC. Hepatol Commun 2022. [PMID: 35238496 DOI: 10.1002/hep4.1928] [Reference Citation Analysis]